Why Did KPRX Stock Surge 17% Pre-Market Today?

• The financing includes $5 million in upfront proceeds and $19 million tied to the exercise of warrants.
• Funds will be used to support general operations, business development, and ongoing research and development, the company said.
• Recently, Kiora’s trial to treat retinitis pigmentosa entered the patient dosing phase.

Shares of Kiora Pharmaceuticals, Inc. (KPRX) jumped more than 17% in pre-market trading on Tuesday after the company unveiled a $24 million private placement deal, signaling fresh support for its ongoing eye disease treatment pipeline.

If the premarket levels hold after the opening bell, KPRX shares would trade at their highest levels in more than two months.

KPRX To Receive $5 Million Upfront

The financing includes $5 million in upfront proceeds, with an additional $19 million tied to the potential exercise of milestone-based warrants. The investment was led by Perceptive Advisors and ADAR1 Capital Management.

The offering was priced at-the-market, with each share and prefunded warrant sold together at $2.543. These include short-term Tranche A-1 warrants and longer-term Tranche A-2 warrants, both exercisable at $1.94 per share. The Tranche A-2 warrants are valid for up to four years, but their term shortens to 30 days once any of Kiora completes enrolment in a Phase 3 trial.

KPRX stock closed at $2.02 on Monday.

Kiora said it plans to use the initial funds to support general operations, business development, and ongoing research and development.

Recently, Kiora advanced its pipeline with KIO-301 entering patient dosing in the Phase 2 ABACUS-2 trial for retinitis pigmentosa, a rare disease that causes retinal degeneration.

How Did Retail Traders React?

Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.

Chatter was mixed, with one user calling the placement “solid news.”

Another user expects the stock to fall below $1 by the end of the week.

Year-to-date, the stock has climbed by around 2%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.